Akanda Receives Nasdaq Delisting Notice, Shares Slump 14%
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
akandanasdaq
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares of cannabis firm Akanda Corp. fell 14% on May 22, 2026 after the company disclosed a Nasdaq non-compliance notice. The exchange issued the letter because Akanda's share price closed below the required $1.00 minimum bid price for 30 consecutive business days. The company now has 180 calendar days to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive days.
Nasdaq listing rules require companies to maintain a minimum bid price of $1.00. Failure to meet this standard triggers a compliance notice. Companies then enter a 180-day cure period to restore their share price above the threshold.
The last comparable event for U.S.-listed cannabis operators occurred in May 2025 when Aurora Cannabis received a similar notice from the New York Stock Exchange. Aurora's shares traded at $0.78 at the time of the notice and ultimately regained compliance after a 1-for-10 reverse stock split.
The current macro backdrop features elevated interest rates, with the Federal Funds target range at 5.25-5.50%. This tight monetary environment pressures speculative growth stocks and capital-intensive sectors like cannabis. The triggering event was Akanda's share price closing below $1.00 from April 1 through May 20, 2026.
Cannabis operators face persistent regulatory headwinds despite incremental legalization progress. The lack of U.S. federal banking reform and sustained Schedule I classification constrains institutional investment. These sector-wide challenges exacerbate individual company compliance risks.
Akanda's stock closed at $0.68 on May 22, 2026. The 14% single-day drop followed the compliance disclosure. The company's market capitalization stands at approximately $8.2 million.
The stock has declined 52% year-to-date against the Nasdaq Composite's gain of 7%. Akanda shares last traded above the $1.00 compliance threshold on March 28, 2026 at $1.02.
A comparison of recent non-compliance events shows distinct recovery patterns.
| Company | Notice Date | Price at Notice | Recovery Action | Outcome |
|---|---|---|---|---|
| Sundial Growers | Aug 2023 | $0.89 | Reverse Split | Regained Compliance |
| Aurora Cannabis | May 2025 | $0.78 | Reverse Split | Regained Compliance |
| Akanda Corp. | May 2026 | $0.68 | Pending | Pending |
Peer cannabis operator Tilray Brands trades at $2.14, while Canopy Growth Corporation trades at $0.91. The AdvisorShares Pure US Cannabis ETF MSOS has declined 18% year-to-date.
The non-compliance notice creates immediate pressure for Akanda to execute a reverse stock split. This corporate action typically requires shareholder approval and carries negative signaling effects. Reverse splits often precede further dilution as companies seek to raise capital at higher nominal share prices.
Second-order effects may benefit larger, compliant cannabis operators. Institutional funds restricted from sub-$1 stocks could reallocate toward Tilray Brands or Green Thumb Industries. The MSOS ETF may experience constituent turnover if Akanda delists, potentially increasing weightings for multi-state operators like Curaleaf.
A counter-argument suggests the notice presents a contrarian opportunity. Some micro-cap specialists target sub-$1 stocks facing technical delisting pressure, betting on successful reverse splits and subsequent momentum. This strategy carries high failure risk, as evidenced by numerous cannabis companies that executed reverse splits only to decline further.
Positioning data shows elevated short interest in Akanda at 8% of float. Options flow indicates increased put buying for July 2026 expiration. The limited public float of 12 million shares amplifies volatility during compliance-driven corporate actions.
Investors should monitor Akanda's formal response plan, due within 45 days of the May 22 notice. The company must submit a compliance strategy to Nasdaq by July 6, 2026. The most likely outcome is a shareholder vote on a reverse stock split ratio between 1-for-10 and 1-for-20.
Key price levels include the $0.50 psychological support and the $1.00 compliance threshold. A break below $0.50 could accelerate declines toward the 52-week low of $0.42. Regaining $0.85 would represent a 25% move from current levels and signal potential consolidation.
The next major catalyst is Akanda's second quarter 2026 earnings report, expected in August. Revenue growth above 15% quarter-over-quarter could improve sentiment. Any announcement regarding strategic partnerships or asset sales would provide liquidity information.
If Akanda executes a reverse split, subsequent trading volume and institutional ownership changes will determine sustainability. Previous cannabis reverse splits saw 60% of companies trade below their post-split price within six months.
If Akanda's share price remains below $1.00 after the 180-day cure period ends in late November 2026, Nasdaq will issue a delisting determination. The company could appeal to a Nasdaq hearings panel, which may grant an additional 180-day extension. During any appeal process, shares continue trading. Final delisting would move Akanda to over-the-counter markets, reducing liquidity and institutional accessibility.
Akanda's situation mirrors Aurora Cannabis's 2025 notice but differs in scale. Aurora had a $300 million market cap versus Akanda's $8 million. Larger companies typically have more options, including direct listings on alternative exchanges or strategic acquisitions. Smaller operators like Akanda face greater financing constraints, making reverse splits more probable. The cannabis sector has seen 14 similar compliance notices since 2023, with 9 resulting in reverse splits.
Retail investors face dilution risk if Akanda executes a reverse split followed by equity fundraising. Share counts decrease proportionally during a reverse split, but subsequent capital raises typically issue new shares. Investors should review proxy statements for split ratio recommendations and assess the company's cash position. Akanda reported $4.1 million in cash as of March 2026, suggesting potential need for additional financing within 12 months regardless of listing status.
Akanda's Nasdaq notice reflects sector-wide pressures that disproportionately impact small-cap cannabis operators with limited financing options.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.